Parker Institute for Cancer Immunotherapy invests another $125M into research

As brand drug nam­ing gets more dif­fi­cult, some ther­a­py ar­eas like obe­si­ty and Alzheimer’s dis­ease are fac­ing even more chal­lenges. That’s be­cause both are tra­di­tion­al­ly

Cal­i­for­nia biotech start­up Or­so­Bio is bet­ting the fu­ture of obe­si­ty drugs lies in com­bi­na­tion ap­proach­es. To get there, Or­so­Bio told End­points News that it raised